Literature DB >> 31558663

European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia.

Liesbeth Duijts1,2, Evelien R van Meel3, Laura Moschino4, Eugenio Baraldi4, Magda Barnhoorn5, Wichor M Bramer6, Charlotte E Bolton7, Jeanette Boyd8, Frederik Buchvald9, Maria Jesus Del Cerro10, Andrew A Colin11, Refika Ersu12,13, Anne Greenough14, Christiaan Gremmen5, Thomas Halvorsen15,16, Juliette Kamphuis8, Sailesh Kotecha17, Kathleen Rooney-Otero18, Sven Schulzke19, Andrew Wilson20, David Rigau21, Rebecca L Morgan22, Thomy Tonia23, Charles C Roehr24,25, Marielle W Pijnenburg3.   

Abstract

This document provides recommendations for monitoring and treatment of children in whom bronchopulmonary dysplasia (BPD) has been established and who have been discharged from the hospital, or who were >36 weeks of postmenstrual age. The guideline was based on predefined Population, Intervention, Comparison and Outcomes (PICO) questions relevant for clinical care, a systematic review of the literature and assessment of the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. After considering the balance of desirable (benefits) and undesirable (burden, adverse effects) consequences of the intervention, the certainty of the evidence, and values, the task force made conditional recommendations for monitoring and treatment of BPD based on very low to low quality of evidence. We suggest monitoring with lung imaging using ionising radiation in a subgroup only, for example severe BPD or recurrent hospitalisations, and monitoring with lung function in all children. We suggest to give individual advice to parents regarding daycare attendance. With regards to treatment, we suggest the use of bronchodilators in a subgroup only, for example asthma-like symptoms, or reversibility in lung function; no treatment with inhaled or systemic corticosteroids; natural weaning of diuretics by the relative decrease in dose with increasing weight gain if diuretics are started in the neonatal period; and treatment with supplemental oxygen with a saturation target range of 90-95%. A multidisciplinary approach for children with established severe BPD after the neonatal period into adulthood is preferable. These recommendations should be considered until new and urgently needed evidence becomes available.
Copyright ©ERS 2020.

Entities:  

Mesh:

Year:  2020        PMID: 31558663     DOI: 10.1183/13993003.00788-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

1.  Bronchopulmonary Dysplasia and Pulmonary Hypertension. The Role of Smooth Muscle adh5.

Authors:  Thomas M Raffay; Koby Bonilla-Fernandez; Anjum Jafri; Ramadan B Sopi; Laura A Smith; Feifei Cui; Maureen O'Reilly; Rongli Zhang; Craig A Hodges; Peter M MacFarlane; Gail Deutsch; Richard J Martin; Benjamin Gaston
Journal:  Am J Respir Cell Mol Biol       Date:  2021-07       Impact factor: 6.914

Review 2.  Bronchopulmonary Dysplasia: Then, Now, and Next.

Authors:  Michael C Tracy; David N Cornfield
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-09       Impact factor: 0.885

3.  Steroid use for established bronchopulmonary dysplasia: study protocol for a systematic review and meta-analysis.

Authors:  Sabina Strashun; Joanna Seliga-Siwecka; Roberto Chioma; Kinga Zielińska; Krzysztof Włodarczyk; Eduardo Villamor; Roy K Philip; Niazy Al Assaf; Maria Pierro
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

4.  Pulmonary hypertension in extremely preterm infants: a call to standardize echocardiographic screening and follow-up policy.

Authors:  Sanne Arjaans; Elvira A H Zwart; Marc Roofthooft; Elisabeth M W Kooi; Arend F Bos; Rolf M F Berger
Journal:  Eur J Pediatr       Date:  2021-02-02       Impact factor: 3.183

5.  Medication utilization in children born preterm in the first two years of life.

Authors:  Jonathan C Levin; Andrew L Beam; Kathe P Fox; Kenneth D Mandl
Journal:  J Perinatol       Date:  2021-02-05       Impact factor: 2.521

6.  Insurance coverage and respiratory morbidities in bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Michael C Tracy; Catherine A Sheils; Jessica L Rice; Lawrence M Rhein; Leif D Nelin; Paul E Moore; Winston M Manimtim; Jonathan C Levin; Khanh Lai; Lystra P Hayden; Julie L Fierro; Eric D Austin; Stamatia Alexiou; Amit Agarwal; Natalie Villafranco; Roopa Siddaiah; Antonia P Popova; Ioana A Cristea; Christopher D Baker; Manvi Bansal; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2022-04-26

7.  ERS International Congress 2019: highlights from Best Abstract awardees.

Authors:  Lorna E Latimer; Marieke Duiverman; Mahmoud I Abdel-Aziz; Gulser Caliskan; Sara M Mensink-Bout; Alberto Mendoza-Valderrey; Aurelien Justet; Junichi Omura; Karthi Srikanthan; Jana De Brandt
Journal:  Breathe (Sheff)       Date:  2019-12

8.  Study protocol: azithromycin therapy for chronic lung disease of prematurity (AZTEC) - a randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants.

Authors:  John Lowe; David Gillespie; Marie Hubbard; Lei Zhang; Nigel Kirby; Timothy Pickles; Emma Thomas-Jones; Mark A Turner; Nigel Klein; Julian R Marchesi; Kerenza Hood; Janet Berrington; Sailesh Kotecha
Journal:  BMJ Open       Date:  2020-10-06       Impact factor: 2.692

9.  Respiratory management of infants with chronic neonatal lung disease beyond the NICU: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Nitin Kapur; Gillian Nixon; Philip Robinson; John Massie; Bernadette Prentice; Andrew Wilson; Sandra Schilling; Jacob Twiss; Dominic A Fitzgerald
Journal:  Respirology       Date:  2020-06-08       Impact factor: 6.424

10.  Agreement between spirometry and impulse oscillometry for lung function assessment in 6-year-old children born extremely preterm and at term.

Authors:  Lundberg Björn; Melén Erik; Thunqvist Per; Norman Mikael; Hallberg Jenny
Journal:  Pediatr Pulmonol       Date:  2020-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.